Johnson & Johnson (JNJ) Construction in Progress (2010 - 2021)

Johnson & Johnson's (JNJ) quarterly Construction in Progress came in at $4.3 billion in Q1 2021, up 18.67% year-on-year from $3.6 billion in Q1 2020, and up 18.67% quarter-over-quarter from $3.6 billion in Q4 2019.

Johnson & Johnson (JNJ) Construction in Progress (2010 - 2021) Analysis & Trends

Johnson & Johnson has disclosed Construction in Progress across 10 years of filings, most recently posting $4.3 billion for Q1 2021.

  • Construction in Progress for Q1 2021 came in at $4.3 billion, up 18.67% year-over-year; the trailing twelve-month figure through Jan 2021 was $4.3 billion (up 18.67% YoY), and the FY2021 annual result was $4.3 billion, up 18.67% from the prior year.
  • Construction in Progress came in at $4.3 billion for Q1 2021 at Johnson & Johnson, up from $3.6 billion in the prior quarter.
  • In the past five years, Construction in Progress ranged from a high of $4.3 billion in Q1 2021 to a low of $3.4 billion in Q1 2017.
  • The 4-year median for Construction in Progress is $3.6 billion (2019), against an average of $3.7 billion.
  • Across the five-year window, Construction in Progress slipped 6.17% in 2019 and rose 18.67% in 2021, its largest moves.
  • Johnson & Johnson's Construction in Progress stood at $3.4 billion in 2017, then gained by 12.41% to $3.9 billion in 2018, then retreated by 6.17% to $3.6 billion in 2019, then advanced by 18.67% to $4.3 billion in 2021.
  • The last three Construction in Progress figures came in at $4.3 billion (Q1 2021), $3.6 billion (Q4 2019), and $3.9 billion (Q4 2018), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Gsk 92,134,969.93 Bn 92,134,964.97 Bn 7.76 Bn -
2 Eli Lilly 1,027.45 Bn 1,022.17 Bn 16.22 Bn -
3 Johnson & Johnson 559.08 Bn 537.03 Bn 15.96 Bn -
4 AbbVie 394.75 Bn 385.40 Bn 10.78 Bn -
5 Merck 295.12 Bn 289.47 Bn 12.09 Bn -
6 Amgen 186.65 Bn 174.61 Bn 5.87 Bn -
7 Gilead Sciences 159.22 Bn 151.50 Bn 5.52 Bn -
8 Pfizer 146.00 Bn 133.23 Bn -1.21 Bn -
9 Bristol Myers Squibb 113.22 Bn 102.77 Bn 8.07 Bn 1.54 Bn
10 Novartis Ag 108.02 Bn 107.33 Bn - -

Historic Data

Download Data
DateValue
Jan 3, 2021 4.32 Bn
Dec 29, 2019 3.64 Bn
Dec 30, 2018 3.88 Bn
Dec 31, 2017 3.45 Bn
Jan 1, 2017 3.35 Bn
Jan 3, 2016 3.53 Bn
Dec 28, 2014 3.60 Bn
Dec 29, 2013 3.30 Bn
Dec 30, 2012 2.74 Bn
Jan 1, 2012 2.50 Bn
Jan 2, 2011 2.58 Bn
Jan 3, 2010 2.52 Bn